NMN vs. NR: What the Human Trials Actually Show About NAD+ Boosters

Behind every NAD+ precursor purchase sits a quiet, reasonable fear: that the cell’s ability to turn food into energy and power its repair enzymes is draining with age, and that the drain could be reversed by swallowing the right molecule. Refill the tank. It is an appealingly mechanical hope — nicotinamide mononucleotide or nicotinamide riboside, two precursors, one missing coenzyme — and it deserves a precise answer rather than either hype or dismissal.

The precise answer splits in two. Both NMN and NR reliably raise NAD+ in the blood in randomized human trials; on that question the evidence is solid. But moving a biomarker is not the same as changing how someone feels or functions, and the downstream health benefits in people remain small, inconsistent, or unproven. The tank can be refilled on paper. Whether that restores what aging took is still an open question.

Both reliably raise blood NAD+

For NR, a 2018 randomized, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults found that six weeks of supplementation was well tolerated and effectively stimulated NAD+ metabolism, confirming the precursor does what it claims at the biochemical level (Martens et al., Nat Commun). For NMN, a 2022 randomized, double-blind, placebo-controlled dose-finding trial in 80 healthy middle-aged adults found that 300, 600, and 900 mg daily all significantly raised blood NAD+ over 60 days, with the effect appearing to plateau around 600 mg (Yi et al., Geroscience). That trial also reported improvements in a six-minute walking test, but it used a per-protocol analysis and surrogate measures, so the functional findings should be read as preliminary rather than definitive.

The recent head-to-head study

Until recently, no human study had compared the precursors directly. A 2026 randomized, placebo-controlled trial in 65 healthy adults did exactly that, testing NMN, NR, and plain nicotinamide side by side for 14 days (Christen et al., Nat Metab). NR and NMN raised circulating NAD+ to a comparable degree, while nicotinamide did not produce the same sustained rise, instead causing only a transient, acute shift in the blood NAD+ metabolome. The study also reported that gut microbes convert NR and NMN into nicotinic acid, suggesting the bacteria in your gut help determine how well these supplements work. In other words, for the narrow job of raising blood NAD+, NMN and NR look roughly interchangeable, and how an individual responds may depend partly on their microbiome.

Where the benefits get thin

Raising a biomarker is not the same as improving health. The 2018 NR trial found no significant overall improvement in blood pressure or arterial stiffness; the authors framed those as hypotheses worth testing in future trials, not established benefits. Disease-focused trials have shown scattered, preliminary signals. A phase I trial of NR in newly diagnosed Parkinson's disease found NR raised brain NAD+ and was associated with mild, variable clinical change in a small group (Brakedal et al., Cell Metab), and a small trial in chronic obstructive pulmonary disease reported reduced airway inflammation (Norheim et al., Nat Aging). These are early, small, and disease-specific, not evidence that NAD+ boosters slow aging in otherwise healthy people. Larger and longer trials are needed before any healthspan claim is warranted.

The US regulatory wrinkle

NMN's legal status in the United States is genuinely unsettled. The FDA has taken the position that NMN cannot be sold as a dietary supplement because it was previously investigated as a drug, which has pushed some retailers to pull or relabel products. NR does not carry the same cloud. This is a regulatory dispute, not a safety verdict, but it is a real reason the two precursors are not in the same position on US shelves, and it can affect what you are actually able to buy.

Educational, not medical advice. If you are considering an NAD+ precursor, the realistic expectation is a measurable rise in blood NAD+ and, so far, uncertain clinical benefit. Talk to a clinician, especially if you take other medications. Educational, not medical advice.